restenosis

Cilostazol reduces restenosis of DES in lesions larger than 40 mm.

Original title: Comparison of Dual Versus Triple Antiplatelet Therapy After Drug-Eluting Stent According to Stent Length (from the Pooled Analysis of DECLARE Trials). Reference: Seung-Whan Lee et al. Am J Cardiol 2013, article in press. Cilostazol, an inhibitor of phosphodiesterase III , associated with aspirin and clopidogrel showed decrease angiographic restenosis both in conventional stents as well as...

Paclitaxel eluting balloon . More effective in restenosis of BMS than DES

Original title: A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Referencia: Seiji Habara et al. Am Heart J 2013;166:527-533.e2. Paclitaxel – eluting balloons have recently emerged as an option for treating in-stent restenosis, both conventional stents ( BMS ) and with drugs (DES )....

Zotarolimus-eluting stent in-stent restenosis

Original title: Clinical Outcomes of the Resolute Zotarolimus-Eluting Stent in Patients With In-Stent Restenosis Two-Year Results From a Pooled Analysis. Reference: Gert Richardt et al. J Am Coll Cardiol Intv 2013, article in press. Previous studies reported a target lesion revascularization (TLR) of 15% and target vessel (TVR) of 22%  after a year of treating an injury-stent restenosis....

Colchicine could reduce restenosis in diabetic patients treated with BMS

Original title: Colchicine Treatment for the Prevention of Bare-Metal Stent Restenosis in Diabetic Patients. Reference: Spyridon Deftereos et al. J Am Coll Cardiol 2013;61:1679–85. In stent restenosis is more frequent in diabetic patients, who therefore find DES particularly beneficial. However, there is a subset of these patients with contraindication to prolonged double antiaggregation, due to a programmed surgery...

The largest series of femoropopliteal in-stent restenosis to date 

Original title: Treatment of Femoropopliteal In-Stent Restenosis With Paclitaxel-Eluting Stents. Zilver PTX Global Registry. ZILVER-PTX. Reference: Thomas Zeller et al. J Am Coll Cardiol Intv 2013;6:274–81. Femoropopliteal in-stent restenosis (ISR) is reported in between 19% and 37% of lesions a year and this incidence increases with lesion length.  The ZILVER-PTX study tested the self-expanding paclitaxel-eluting nitinol stent (Cook...

Strategies for treating left coronary trunk restenosis.

Original title: Clinical and Procedural Predictors of Suboptimal Outcome After the Treatment of Drug-Eluting Stent Restenosis in the Unprotected Distal Left Main Stem The Milan and New-Tokyo (MITO) Registry. Reference: Circ Cardiovasc Interv. 2012;5: 491-498 We have very little data on the percutaneous treatment of restenosis of an unprotected LMCA.  The aim of this study was to evaluate...

Future strategies to prevent restenosis and stent thrombosis

Original title: Endothelial cell repopulation after stenting determines in-stent neointima formation: effects of bare-metal vs. drug-eluting stents and genetic endothelial cell modification. Reference: Douglas G et al. European Heart Journal doi:10.1093/eurheartj/ehs240 Experimental models of vascular injury have shown that the rate of endothelial cell repopulation post-injury is a critical factor in determining subsequent neointima formation as well as...

Cilostazol reduces restenosis in infrapopliteal angioplasty

Original title: Impact of Cilostazol on Angiographic Restenosis after Balloon Angioplasty for Infrapopliteal Artery Disease in Patients with Critical Limb Ischemia Reference: Y. Soga et al. European Journal of Vascular and Endovascular Surgery 44 (2012) 577e581. Angioplasty is regularly used for patients with critical limb ischemia where restenosis is a great limitation, especially in infrapopliteal territory.  The use...

A new paradigm in the treatment of in-stent restenosis?

Original title: ISAR DESIRE 3: Drug-eluting balloon is best option for restenosis of limus-eluting stents Reference: Dr Robert Byrne. TCT 2012. Miami, Fl. The first of the ISAR DESIRE trials showed that drug-eluting stents (DES) were the best strategy for treating restenosis of a bare metal stent, the second ISAR DESIRE trial tested the hypothesis of changing or...

Top